We are live on ! Find out more
GNCA

Genocea Biosciences, Inc.
GNCA

Delisted

GNCA was delisted on the 2nd of June, 2022.

Back to rankings

40 hedge funds and large institutions have $42.1M invested in Genocea Biosciences, Inc. in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

748% more call options, than puts

Call options by funds: $712K | Put options by funds: $84K

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

8% more capital invested

Capital invested by funds: $38.9M → $42.1M (+$3.16M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less funds holding

Funds holding: 41 → 40 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
40
Holders Change
-1
Holders Change %
-2.44%
% of All Funds
0.63%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
11
Reduced
7
Closed
4
Calls
$712K
Puts
$84K
Net Calls
+$628K
Net Calls Change
+$403K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$92.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$51.9K
3
BC
BIT Capital
Germany
+$38.1K
4
Millennium Management
Millennium Management
New York
+$20.2K
5
Jane Street
Jane Street
New York
+$20.1K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$83.4K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$25K
3
Simplex Trading
Simplex Trading
Illinois
-$24K
4
VF
Virtu Financial
New York
-$15K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$13.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$20K – – –
Wells Fargo
27
Wells Fargo
California
$20K +$7.63K +7,001 +74%
PCA
28
Personal Capital Advisors
California
$19K – – –
WA
29
WealthTrust Axiom
Pennsylvania
$18K – – –
CAAS
30
Capital Asset Advisory Services
Michigan
$15K – – –
Two Sigma Advisers
31
Two Sigma Advisers
New York
$13K -$13.8K -12,677 -56%
EAM
32
Empirical Asset Management
Massachusetts
$13K – – –
Simplex Trading
33
Simplex Trading
Illinois
$11K -$24K -22,039 -71%
TRCT
34
Tower Research Capital (TRC)
New York
$7K -$230 -211 -3%
ACM
35
ACT Capital Management
Pennsylvania
$6K – – –
First Manhattan
36
First Manhattan
New York
$3K – – –
AWA
37
Artemis Wealth Advisors
New York
$1.42K – – –
Federated Hermes
38
Federated Hermes
Pennsylvania
$1K -$144 -132 -13%
CG
39
Cutler Group
California
$1K – – –
CSS
40
Cubist Systematic Strategies
Connecticut
$1K +$980 +900 New
Acadian Asset Management
41
Acadian Asset Management
Massachusetts
– -$25K -21,741 Closed
VF
42
Virtu Financial
New York
– -$15K -12,503 Closed
VRM
43
Vectors Research Management
New York
– -$7K -6,000 Closed
UBS Group
44
UBS Group
Switzerland
– -$1K -1,129 Closed
1
2

GNCA Hedge Fund Activity: Q1 2022 in Review

40 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q1 2022, worth a combined $42.1M — up 8.1% from $38.9M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of GNCA and 3 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 11 added.

The largest buyer was Geode Capital Management, adding an estimated $92.4K. The largest seller was Point72 Asset Management, cutting an estimated $83.4K.

  • 40 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q1 2022, down from 41 in Q4 2021.
  • Funds reported $42.1M of Genocea Biosciences, Inc. stock for Q1 2022, up 8.1% quarter-over-quarter.
  • 3 funds opened new Genocea Biosciences, Inc. positions in Q1 2022 and 4 closed out, a net change of -1 holder.
  • The largest Genocea Biosciences, Inc. buyer in Q1 2022 was Geode Capital Management, an estimated $92.4K added.
  • The largest Genocea Biosciences, Inc. seller in Q1 2022 was Point72 Asset Management, an estimated $83.4K sold.

Based on aggregated 13F filings for Q1 2022.